Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 27, 2025
Daily News
October 27, 2025
- First Oral Small-Molecule GLP-1 Nears Filing; Broad Use Expected in Diabetes
October 27, 2025
- Chugai Acquires Renalys Pharma, Bags IgAN Drug
October 27, 2025
- Takaichi Vows Cross-Party Talks on Social Security Reform
October 27, 2025
- Astellas to Build Next-Gen Pipeline in I/O and Protein Degradation: R&D Chief
October 27, 2025
- The Price of Stability: Who Bears Japan’s Drug Distribution Burden?
October 27, 2025
- Chuikyo Members Call for Revising Clozapine Fee Criteria to “Hospital-Based” Calculation
October 27, 2025
- AstraZeneca Sees Imfinzi’s Bladder Cancer Nod as Key New Indication
October 27, 2025
- Japan Panel OKs PCV20 as Routine Pneumococcal Shot for Elderly
October 27, 2025
- Japan Panel Backs NIP Use of High-Dose Flu Shot; Talks Continue on RSV Prevention
October 27, 2025
- EA Pharma Files to Add Dosage for 1-Year-Olds to Movicol
October 27, 2025
- Makoto Oniki Tapped as Head of LDP’s Health Division
October 27, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…